Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLYcemic Control with Empagliflozin vs Standard of Care in Type 2 Diabetes and Heart Failure
2018-000832-82Phase 4Completed
- Sponsor
- Fondazione Toscana Gabriele Monasterio
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) and heart failure (HF) comparing Empagliflozin plus standard of care with Standard of care alone (2 arms). Primary endpoint: Primary: 1-year variation in NT-proBNP plasma concentrations. Started Jun 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on 2018-000832-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000832-82.